Drug Trial Radar · NCT04417517
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
65
Actual
Start
Oct 2, 2020
Primary completion
Jan 17, 2025
Study completion Jun 10, 2025
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Conditions
- Higher Risk Myelodysplastic Syndromes
Interventions
evorpaceptDrug
Fusion protein that blocks CD47-SIRPalpha pathway
azacitidineDrug
Hypomethylating agent (HMA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Dose Limiting Toxicities (DLT)Time frame: Up to 28 days
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Approximately 2 years
- Phase 2: Complete response rate (CRR)Time frame: Approximately 6 months
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
University of Southern California, Norris Comprehensive Cancer Center
Los Angeles, California
Northwestern University Feinberg School of Medicine
Chicago, Illinois
IU Simon Cancer Center
Indianapolis, Indiana
START Midwest
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Levine Cancer Institute
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul Saint Mary's Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Hospital General Universitario de Alicante
Alicante, Spain
Hospital San Pedro de Alcantara
Cáceres, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.